GSK gets second cancer drug approval from Nuvalent buy
GSK's Nelkarmi (neladalkib) received FDA approval for ALK-positive NSCLC after prior ALK inhibitor treatments. The approval follows GSK's $10.6B acquisition of Nuvalent. Analysts project Nelkarmi, Jideytro, and NVL-330 could generate $5B-$7B in annual sales. Nelkarmi showed a 49% objective response rate in trials. GSK aims to boost revenues to £40B by 2031.
How this was made

The 30-second read
Why it matters
This is a direct regulatory milestone that can change commercial expectations for GSK’s oncology segment and validate the Nuvalent pipeline strategy, while leaving pricing and confirmatory evidence as key uncertainties.
Market read
Traders can reassess GSK’s oncology growth trajectory as a second Nuvalent-derived drug gains FDA clearance, supported by ALKOVE-1 response and durability data.
What to watch
The article notes GSK has not yet revealed US list price, and the competitive ALKAZAR head-to-head versus Alecensa could shift uptake expectations.
Background
GSK acquired Nuvalent earlier this year and is now receiving FDA clearances for multiple targeted NSCLC drugs, including ROS1 inhibitor Jideytro and now ALK inhibitor Nelkarmi.
Ticker impact
FDA cleared GSK’s ALK inhibitor Nelkarmi for advanced ALK-positive NSCLC, the second oncology product from its Nuvalent acquisition.
Likely positive bias as investors price in incremental oncology revenue and validate the Nuvalent pipeline execution.
The article reports a fresh FDA clearance for Nelkarmi, includes trial efficacy metrics, and frames it as a second Nuvalent-derived oncology product, which is directly tradable for a biotech/pharma holder.
Market effects
Reinforces competitive momentum in ALK/ROS1 NSCLC targeted therapies and supports the broader oncology pipeline narrative for large pharma post-acquisition.
Primarily US regulatory-driven, but can influence European pharma sentiment given GSK’s UK base.
Could affect global ALK/ROS1 treatment sequencing expectations and competitive positioning across major markets.
Counterpoint
Accelerated approvals can face future confirmatory-trial risk, so near-term enthusiasm may over-discount durability and label expansion outcomes.
Key entities
- companyGSK
Sponsor of Nelkarmi (neladalkib) and acquirer of Nuvalent, receiving FDA clearance for an ALK-positive NSCLC indication.
- companyNuvalent
Biotech acquired by GSK earlier this year; its pipeline is now producing FDA-cleared oncology products.
- regulatorFDA
Cleared Nelkarmi for advanced ALK-positive NSCLC under an accelerated approval pathway.




